Advanced Search


Study ID Status Title Patient Level Data
207266082 Completed A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients with Symptomatic Persistent Atrial Fibrillation (AF)
207267 Not yet recruiting Assessment of Patients Treated with Albiglutide – Phase 2
207271 Not yet recruiting A multicentre study to measure the impact of rotavirus (RV) vaccine on acute gastroenteritis (AGE) hospitalizations in children < 5 years of age attending hospitals in Saudi Arabia
207323 Active, not recruiting Burden of illness among patients with eosinophilic severe COPD
207347 Completed Persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects from the HPV-058 study
207348 Completed Meta-analysis of studies MEA112997 and MEA115588 of mepolizumab (SB240563) in severe asthma – additional subgroup analyses of exacerbations and investigation of relationship of FEV1 to exacerbations (eTrack Study Identifier 207348)
207350 Recruiting A prospective, multi-centre post marketing surveillance (PMS) cohort study to monitor the safety of GlaxoSmithKline (GSK) Biologicals’ Human papillomavirus (HPV)-16/18 L1 VLP AS04 vaccine in female Chinese subjects aged between 9 and 45 years, when administered according to the Prescribing Information (PI) as per routine practice.
207351 Active, not recruiting Observational Study to Assess Maternal and Fetal Outcomes Following Exposure to Albiglutide during Pregnancy
207382 Active, not recruiting Patient phenotypes and treatment pathways in Primary Sjogren’s Syndrome: an international cross-sectional survey of Rheumatologists and adult Primary Sjögren’s Syndrome patients with systemic involvement (Adelphi 2018 pSS Disease Specific Programme)
207387 Completed PGx7665: Exploratory Pharmacogenetic analysis of response to GSK2269557, a PI3 kinase delta inhibitor in patients from study 116678 with COPD
207388 Completed PGx7666: Exploratory pharmacogenetic investigation of efficacy response to advair in COPD studies 116135, 116136, 111117, 114930, 114951, 116134, 112352, 113107, 113109, 116974
207389 Completed PGx7667 (207389) Exploratory Pharmacogenetic Investigation of Efficacy Response to mepolizumab in Eosinophilic Granulomatosis Polyangiitis (Churg-Strauss Syndrome) PGstudy 115921
207390 Not yet recruiting PGx7669: an exploratory pharmacogenetic efficacy investigation of steroid reduction in subjects with severe asthma treated with mepolizumab in 115575 and 115661
207435 Not yet recruiting An open label, multi-centre, post marketing surveillance to observe the safety and effectiveness of ARNUITY administered in patients with Asthma in usual practice
207440 Completed A Phase I, First Time in Human, Two Part, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Single and Repeat Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3352589, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers
207449 Active, Not Recruiting Ulcerative Colitis and Crohn’s Disease: Resource Utilization and costs after initiation of biologics
207451 Completed A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm
207464 Recruiting A randomised, placebo-controlled, double-blind (sponsor open), segmental LPS challenge study to investigate the pharmacodynamics of GSK2798745 in healthy participants
207467 Recruiting Immunogenicity, reactogenicity and safety study of different formulations of GSK Biologicals' Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) when administered to healthy adolescents and young adults 10 to 40 years of age
207468 Completed A Proof of Concept (POC) Clinical Study to Evaluate the Appearance of Fine Lines and Wrinkles on a Developmental Cosmetic Moisturising Cream in Healthy Subjects Presenting Visible Signs of Ageing
207478 Completed Meta-Analysis Plan for GSK sponsored studies MEA117113 and MEA117106 of Mepolizumab (SB240563) in COPD – Analysis to assess effect of mepolizumab on rate of exacerbations requiring an emergency department visit or hospitalization and rate of severe exacerbations (eTrack Study Identifier 207478)
207488 Not yet recruiting Effects of oral ambrisentan on echocardiographic measures of right ventricular structure and function in Chinese patients with pulmonary arterial hypertension
207489 Recruiting An observer-blind study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3277511A when administered to COPD patients
207497 Recruiting A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – DREAMM-6
207521 Completed PGx7673: Confirmatory Genetics Reporting and Analysis Plan: Efficacy pharmacogenetic analysis of SLE patients treated with Benlysta in study BEL113750 (eTrack Study ID 207521)



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.